Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD
J. F. Donohue, J. A. van Noord, S. J. Langley, A. Lee, S. Kesten, L. J. Towse (Chapel Hill, Ridgefield, United States Of America; Heerlen, The Netherlands; Manchester, Bracknell, United Kingdom)
Source: Annual Congress 2001 - COPD
Session: COPD
Session type: Poster Discussion
Number: 289
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. F. Donohue, J. A. van Noord, S. J. Langley, A. Lee, S. Kesten, L. J. Towse (Chapel Hill, Ridgefield, United States Of America; Heerlen, The Netherlands; Manchester, Bracknell, United Kingdom). Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD. Eur Respir J 2001; 16: Suppl. 31, 289
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Sustained FEV1 increases in COPD patients induced by salmeterol 50 mcg twice daily via the diskus inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 240s Year: 2002
Formoterol Turbuhaler® twice daily is more cost-effective than salmeterol twice daily or as-needed salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 330s Year: 2001
Superior spirometric efficacy of single dose formoterol compared to single dose salmeterol during the first hour post-dose in moderate and severe COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 57s Year: 2001
Once daily ciclesonide and twice daily fluticasone propionate are equally effective in the treatment of patients with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 346s Year: 2004
Improvement in dyspnea with fluticasone/salmeterol compared with salmeterol or ipratropium in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 88s Year: 2004
The bronchodilatory effect of NVA237 inhaled once daily in patients with COPD Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Comparable efficacy of ciclesonide 160 μg once daily and budesonide 200 μg twice daily in patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005
Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006
Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 14s Year: 2005
Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Financial benefits of fluticasone propionate/salmeterol 250/50 mcg fixed dose combination over tiotropium in elderly managed COPD patient Source: Annual Congress 2010 - Management of airway disease Year: 2010
LATE-BREAKING ABSTRACT: Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: The SHINE study Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Inhaled budesonide 800 μg once daily versus 400 μg twice daily in patients with mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 97s Year: 2001
Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD Source: Eur Respir J 2013; 42: 539-541 Year: 2013
Ciclesonide 80 μg or 160 μg once daily is comparable to fluticasone propionate 88 μg twice daily in the treatment of asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005
24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Improvements in FEV1 and symptoms in poorly-reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001